

## Auris Medical News Release

### Auris Medical Promotes Anne Sabine Zoller to General Counsel

**Zug, Switzerland, August 3, 2015** – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced the promotion of Anne Sabine Zoller to General Counsel and member of the Executive Management team. Ms Zoller acquired extensive experience in Swiss and international corporate law as attorney and in-house counsel.

Prior to joining Auris Medical in April 2015 as Senior Legal Counsel, Ms Zoller was an attorney in the Corporate/M&A team of Homburger AG, a Zurich based law firm, and later Corporate/M&A Counsel with Straumann Group, a dental implant company headquartered in Basel. She obtained a PhD in law from the University of Zurich and an MBA from Melbourne Business School.

#### About Auris Medical

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".

#### Forward-Looking Statements

*This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or Auris Medical's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the timing and conduct of clinical trials of Auris Medical's product candidates, the clinical utility of Auris Medical's product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical's intellectual property position and Auris Medical's financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical's capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Auris Medical's prospectus relating to its Regis-*

*tration Statement on Form F-1, as amended, and future filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.*

*Contact:*

*Company: Dr. Thomas Meyer, Chairman and CEO, +41 41 729 71 94, [ear@aurismedical.com](mailto:ear@aurismedical.com)*

*Investors: Matthew P. Duffy, Managing Director, LifeSci Advisors, 212-915-0685, [matthew@lifesciadvisors.com](mailto:matthew@lifesciadvisors.com)*